IPSIRIUS
keyboard_backspaceBack to Home
Contact
23 rue Pierre Nicoles
75006 Paris
France
CMO
About us
The company develops next-generation universal immunotherapies based on proprietary and innovative engineered induced pluripotent stem cells (iPSCs). Our platform is uniquely positioned to address three of the most critical unmet needs in oncology: treatment resistance, metastasis, and relapse — the main drivers of cancer mortality and treatment failure. By targeting the most aggressive cancers with scalable, off-the-shelf solutions, we aim to transform the current therapeutic landscape and unlock significant market potential.
Business offer
Go-to-Market & Partnerships:
- Licensing strategy
- Industry and academic collaborations
Activities
- Therapeutic Product
- Oncology
- Cell origin
- Cell Banking
- IPs
- MSC
- CD34 + HSC cells
- Target cell isolation
- iPS reprogramming
- Differentiated Cell
- Production Cell
- Cell modification
- Direct reprogramming
- Cell Activation
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- CMC/analytical quality assessment, quality control
- Safety for gene-edited cells
- translocation
- Non-clinical safety and toxicology studies
- Bioproduction engineering
- Cell Expansion
- Wave bioreactor
- Cell factory
- Organoids culture
- Capsules culture
- Scale-Up
- Process optimization
- Automated manufacturing
- Non-GMP expansion
- GMP expansion
- Other
- CGMP
- Formulation
- Conditioning
- Storage
